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Abstract
Introduction: C-type natriuretic peptide (CNP) is a paracrine molecule which is mainly synthesized in the
vasculature. High levels have been reported in sepsis, and CNP has been proposed as a biomarker predicting sepsis
in traumatized patients. We aimed at evaluating the diagnostic and prognostic value of N-terminal pro-CNP (NT-
proCNP) for predicting sepsis, disease severity and mortality in critically ill medical patients.
Methods: 273 critically ill patients (197 patients with sepsis or septic shock, 76 without evidence of sepsis) and 43
healthy controls were consecutively included in a prospective clinical single-center non-interventional study at the
Medical Intensive Care Unit, RWTH-University Aachen, Germany. Patients’ outcome was followed for about 1 year.
NT-proCNP serum concentrations were determined upon ICU admission, as well as in the mornings of day 3 and
day 7 after admission. Intensive care treatment measures as well as routine and experimental laboratory parameters
were recorded and analyzed.
Results: NT-proCNP serum concentrations upon admission to the ICU were elevated in critically ill patients as
compared with healthy controls. Patients with sepsis had significantly higher NT-proCNP levels than non-sepsis
patients. NT-proCNP was strongly associated with inflammatory parameters (i.e. C-reactive protein, procalcitonin
and TNF-a), biomarkers of organ dysfunction and clinical composite scores (APACHE-II, SOFA, SAPS2). NT-proCNP
levels at admission and day 3 were found to be a strong predictive marker for ICU- and overall survival. Moreover,
a decline of serum NT-proCNP after admission to the ICU was associated with reduced mortality. The predictive
power of serum NT-proCNP was similar to ‘conventional’ prognostic tools such as clinical scores.
Conclusions: NT-proCNP is significantly elevated in critically ill patients, with highest levels in sepsis. Inflammation
as well as organ function are strongly associated with NT-proCNP serum concentrations. Low initial NT-proCNP
levels and a decline during initial treatment indicate a favourable ICU- and long-term outcome.
Introduction
The natriuretic peptide family consists of three distinc-
tive members: atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP) and C-type natriuretic peptide
(CNP). These peptides exert multiple potent diuretic,
natriuretic and vasorelaxant functions, thereby directly
influencing body-fluid homeostasis and blood pressure
control [1,2]. As ANP and BNP are mainly derived from
the heart in response to atrial and ventricular stretching,
they have been thought to act as cardiac hormones and
linked to cardiac dysfunction [2,3]. In patients with
severe sepsis, BNP has been proposed as a useful bio-
marker to predict survival [4,5], most likely by indicating
septic myocardial depression [4,5].
CNP is synthesized as a precursor proCNP protein,
and conversion of proCNP to the biologically active hor-
mone CNP is processed by the intracellular endopro-
tease furin [6]. Amino-terminal pro-C-type natriuretic
peptide (NT-proCNP) is the N-terminal fragment of the
C-type natriuretic peptide precursor. As a cleavage pro-
duct of proCNP, NT-proCNP circulates in equimolar
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t ob eam o r er e l i a b l em a r k e ro ft h ee x t e n to fC N Pb i o -
synthesis [7]. Due to its extra-cardiac origin and its high
expression in the brain, CNP was initially believed to be
a neuropeptide, involved in central regulatory mechan-
isms [8,9]. At present it is known that CNP is widely
expressed in various tissues, with particularly high con-
centrations in the vascular endothelium [10] and chon-
drocytes [11], inducing vasorelaxation and vascular
remodeling, as well as regulating bone growth [12].
Compared with ANP and BNP, CNP exerts limited
diuretic and natriuretic functions, but counteracts angio-
tensin II- or endothelin-1-induced vasoconstriction and
complements the actions of other endothelial vasorelax-
ant mediators such as nitric oxide (NO) and prostacy-
clin [13]. IL-1, endotoxins and particularly TNF-a,
which are increased in states of sepsis, can stimulate
CNP release from isolated endothelial cells and in this
way regulate local vascular tone [14]. CNP release in
response to proinflammatory cytokines suggests an
interaction of macrophageal cytokine synthesis and vas-
cular endothelium [15]. This link indicates a potential
pathophysiological role of CNP in sepsis and septic
shock, which are characterized by arteriolar vasodilata-
tion, hypotension, and inadequate tissue perfusion [16].
In a small cohort of patients with sepsis and septic
shock, high serum CNP concentrations have been
demonstrated [17]. Moreover, in a recent study, NT-
proCNP has been proposed as a novel biomarker for
predicting the development of sepsis in multiple trauma
patients [18]. The diagnostic and prognostic value of
NT-proCNP measurements in critically ill medical
patients is currently unknown.
We therefore conducted a large study with critically ill
patients in a medical ICU, performing longitudinal mea-
surements of NT-proCNP serum concentrations during
the first week of ICU treatment, to address whether
NT-proCNP is activated in critical illness, whether NT-
proCNP has diagnostic value for sepsis and/or multior-
gan failure, and whether NT-proCNP can serve as a
prognostic predictor for ICU and long-term survival.
Materials and methods
Study design and patient characteristics
The study protocol was conducted in accordance with
t h ee t h i c a ls t a n d a r d sl a i dd o w ni nt h eD e c l a r a t i o no f
Helsinki and approved by the local ethics committee
(ethics committee of the University Hospital Aachen,
RWTH-University, Aachen, Germany, reference number
EK 150/06). We investigated 273 patients (172 male,
101 female with a median age of 64 years; range 18 to
90 years) who were admitted consecutively to the Gen-
eral Internal Medicine ICU at the RWTH-University
Hospital Aachen, Germany (Table 1). Written informed
consent was obtained from the patient, his or her
spouse, or the appointed legal guardian. Patients that
were expected to have a short-term (< 72 hours) inten-
sive care treatment due to post-interventional observa-
tion or acute intoxication were not included in this
study [19]. Medium length of stay at the ICU was nine
days (range 1 to 137 days) and medium length of stay in
hospital was 27 days (range 2 to 151 days).
We prospectively collected patient data, clinical infor-
mation and blood samples. The clinical course of
patients was observed in a follow-up period by directly
contacting the patients, the patients’ relatives, or their
primary care physicians. Critical care patients were
divided upon ICU admission into two categories: sepsis
patients and non-sepsis patients. Patients in the sepsis
group met the criteria proposed by the American Col-
lege of Chest Physicians and the Society of Critical Care
Medicine Consensus Conference Committee for severe
sepsis and septic shock [20].
The control group consisted of 43 healthy blood
donors (28 male, 15 female; median age 53 years, range
24 to 68 years) from the local blood transfusion institute
at the University Hospital Aachen. At our blood transfu-
sion institute, all volunteers that donate blood agreed
(after informed consent) to contribute to ongoing bio-
marker studies. All control subjects had normal values
for blood counts, C-reactive protein, and liver enzymes,
and tested negative for hepatitis B and C and HIV.
In addition, ICU patients were divided according to
their Acute Physiology and Chronic Health Evaluation
(APACHE) II score into patients with “moderate disease
severity” (APACHE-II < 10, with a statistical risk of
death below 10%) and “high disease severity” (APACHE-
II > 10) [21].
Characteristics of sepsis and non-sepsis patients
Among the 273 critically ill patients enrolled in this
study, 197 patients conformed to the criteria of bacterial
Table 1 Disease etiology of the study population
Sepsis Non-sepsis
n = 197 n =7 6
Etiology of sepsis critical illness
Site of infection n (%)
pulmonary 117 (60%)
abdominal 30 (15%)
urogenital 10 (5%)
others 40 (20%)
Etiology of non-sepsis critical illness
n (%)
decompensated liver cirrhosis 19 (25%)
cardio-pulmonary disease 25 (33%)
others 32 (42%)
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Page 2 of 10sepsis (Table 1). Non-sepsis patients were admitted to
the ICU mainly due to cardiopulmonary diseases (myo-
cardial infarction, pulmonary embolism, and cardiac pul-
monary edema), decompensated liver cirrhosis, or other
critical conditions, and did not differ in age or sex from
sepsis patients (Table 1). Compared with the cohort of
non-sepsis patients, sepsis patients were more often in
need of mechanical ventilation in the longer term
(Table 2) and displayed significantly higher levels of rou-
tinely used biomarkers of inflammation (i.e. C-reactive
protein, procalcitonin, white blood cell count; data not
shown). Both groups did not differ in APACHE-II score
and simplified acute physiology score (SAPS) 2, vaso-
pressor demand, or laboratory parameters indicating
liver or renal dysfunction (data not shown).
NT-proCNP measurements
Prior to therapeutic interventions, blood samples were
collected upon admission to the ICU, as well as in the
morning of day three and seven after admission. Follow-
ing centrifugation at 2000 g at 4°C for 10 minutes,
serum and plasma aliquots of 1 mL were frozen imme-
diately at -80°C. NT-proCNP serum concentrations
were analyzed using a specific commercial enzyme
immunoassay (#BI-20872, BioMedica, Vienna, Austria;
distributor: Immundiagnostik AG, Bensheim, Germany).
Intra-assay coefficient of variation was 5.3 to 8.3%, and
inter-assay coefficient of variation was 7 to 9%. IL-6, IL-
10, TNF-a (all Siemens Healthcare, Erlangen, Germany),
and procalcitonin (Kryptor, B.R.A.H.M.S. Diagnostica,
Henningsdorf, Germany) were measured by commercial
chemiluminescence assays, following manufacturers’
instructions.
Statistical analysis
Data are given as median and range due to the skewed
distribution of most of the parameters. Differences
between two groups were assessed by Mann-Whitney-
U-test and multiple comparisons between more than
two groups have been conducted by Kruskal-Wallis ana-
lysis of variance and Mann-Whitney-U-test for post hoc
analysis. Box plot graphics illustrate comparisons
between subgroups and they display a statistical sum-
mary of the median, quartiles, range, and extreme
values. The whiskers extend from the minimum to the
maximum value excluding outside and far out values,
which are displayed as separate points. An outside value
(indicated by an open circle) was defined as a value that
is smaller than the lower quartile minus 1.5-times inter-
quartile range, or larger than the upper quartile plus
1.5-times the interquartile range. A far out value (indi-
cated by an asterisk) was defined as a value that is smal-
ler than the lower quartile minus three times
interquartile range, or larger than the upper quartile
Table 2 Baseline patient characteristics and NT-proCNP serum concentrations
Parameter All patients Sepsis Non-sepsis
Number 273 197 76
Sex (male/female) 172/101 128/69 44/32
Age median (range) (years) 64 (18-90) 65 (20-90) 60 (18-85)
APACHE-II score median (range) 17 (2-40) 18 (3-40) 15 (2-31)
SAPS2 score median (range) 44 (0-80) 44.5 (0-79) 41.5 (13-80)
ICU days median (range) 9 (0-137) 12 ** (0-137) 6 ** (1-45)
Hospital days median (range) 27 (2-151) 30 ** (2-151) 14 ** (2-85)
Death during ICU
n (%)
76 (27.8%) 61 (31.0%) 15 (19.7%)
Death during follow up n (%) 132 (50.2%) 101 (53.2%) 31 (42.5%)
Mechanical ventilation n (%) 194 (73.2%) 144 (75%) 50 (68.5%)
Ventilation time median (range) (hours) 126 (0-2966) 180 * (0-2966) 48.5 (0-986)
Pre-existing diabetes n (%) 88 (33.1%) 60 (31.3%) 28 (37.8%)
BMI median (range) (m²/kg) 25.8 (14.0-66.7) 25.9 (14.0-66.7) 25.8 (15.9-53.3)
NT-proCNP day 1 median (range)
(pmol/L)
4.07 (0-42) 5.6 (0-42) ** 1.48 (0-42) **
NT-proCNP day 3 median (range)
(pmol/L)
4.79 (0-42) 5.81 (0-42) * 0.90 (0-42) *
NT-proCNP day 7 median (range)
(pmol/L)
3.91 (0-42) 4.59 (0-42) 2.37 (0-41.34)
APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; NT-proCNP, amino-terminal pro-C-type natriuretic peptide; SAPS, simplified
acute physiology score.
Long-term follow-up data on survival were only available in 263 of 273 patients.
Significant differences between sepsis and non-sepsis patients are marked by *(P < 0.05) or **(P < 0.001).
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Page 3 of 10plus three times the interquartile range [22]. All values,
including “outliers”, have been included for statistical
analyzes. The Wilcoxon signed-rank test was applied as
a non-parametric statistical hypothesis test for compar-
ing repeated measurements (days one, three and seven)
in the same individuals. Correlations between variables
have been analysed using the Spearman correlation
tests, where values of P < 0.05 were considered statisti-
cally significant [23]. The prognostic value of the vari-
ables was tested by univariate and multivariate analyses
in the Cox regression model. Kaplan-Meier curves were
plotted to display the impact on survival [24]. After sig-
nificant results from the univariate and multivariate Cox
regression analyses, Kaplan-Meier curves and log-rank
test calculations were performed subsequently for differ-
e n tc u t - o f fv a l u e sf o rN T - p r o C N P( 5 ,6 ,7 ,8 ,9 ,1 0 ,1 1 ,
and 12 pmol/L). The threshold of 8 pmol/L yielded
highest log-rank values. Receiver operating characteristic
(ROC) curve analysis and the derived area under the
curve (AUC) statistic provides a global and standardized
appreciation of the accuracy of a marker or a composite
score for predicting an event. ROC curves were gener-
ated by plotting sensitivity against 1-specificity. All sta-
tistical analyses were performed with SPSS version 12.0
(SPSS, Chicago, IL, USA).
Results
NT-proCNP serum concentrations upon admission to the
ICU are elevated in critically ill patients as compared with
healthy controls
We first tested whether NT-proCNP is activated in criti-
cally ill patients. Upon admission to the medical ICU,
critically ill patients displayed significantly higher NT-
proCNP serum concentrations as compared with healthy
controls (median 0.34 pmol/L, range 0 to 5.53, in con-
trols versus 4.07 pmol/L, range 0 to 42, in ICU patients,
P < 0.001; Figure 1a). Moreover, NT-proCNP levels
were significantly higher in patients with APACHE-II
scores above 10 in comparison to ICU patients admitted
with APACHE-II scores of 10 or less (Figure 1b), indi-
cating that NT-proCNP is further related to the disease
severity.
NT-proCNP serum concentrations indicate sepsis and
organ failure in medical ICU patients
Based on a recent study that suggested NT-proCNP as a
novel biomarker for predicting sepsis in trauma patients
[18], we tested whether serum NT-proCNP might iden-
tify patients with sepsis in the medical ICU setting as
well. We found significantly elevated NT-proCNP serum
concentrations in septic patients versus patients with
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Figure 1 Serum NT-proCNP concentrations in critically ill patients at ICU admission. (a) Serum amino-terminal pro-C-type natriuretic
peptide (NT-proCNP) concentrations at admission to the medical ICU are significantly (P < 0.001, U-test) elevated in critically ill patients (n = 273)
as compared with healthy controls (n = 43). (b) Serum NT-proCNP concentrations at admission to the medical ICU are significantly (P = 0.009, U-
test) elevated in critically ill patients with high initial Acute Physiology and Chronic Health Evaluation (APACHE) II scores (> 10) in comparison to
patients with low APACHE-II scores (</=10). Box plot are displayed, where the bold line indicates the median per group, the box represents 50%
of the values, and horizontal lines show minimum and maximum values of the calculated non-outlier values; asterisks and open circles indicate
outlier values.
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Li nn o n - s e p s i sp a t i e n t sv e r s u s5 . 6 0p m o l / Li ns e p s i s
patients; Figure 2a and Table 2). We next compared the
diagnostic accuracy of NT-proCNP with classical, routi-
nely used markers of inflammation and bacterial infec-
tion by using ROC curve analyses. C-reactive protein
(CRP) and procalcitonin (PCT) achieved AUC statistics
of 0.852 and 0.783, respectively, while NT-proCNP and
white blood cell count only reached AUC values of
0.661 and 0.560, respectively (Figure 2b). Although our
data demonstrated a strong elevation of NT-proCNP in
critically ill patients upon admission to the ICU, NT-
proCNP itself evidenced inferior diagnostic accuracy for
sepsis as compared with classical biomarkers.
At admission to the ICU, serum NT-proCNP concen-
trations in the total cohort and the subgroup of sepsis
patients were closely correlated to markers of inflamma-
tion and bacterial infection, such as PCT, CRP and
TNF-a (Table 3). We could also reveal strong associa-
tions with renal and hepatic functions in the total
cohort of critically ill patients and in sepsis patients. In
particular, we could show a close association with renal
function as displayed by highly significant correlations
with creatinine, urea, and cystatin C serum concentra-
tions and the glomerular filtration rate of cystatin C
(Table 3), representing potential renal clearance of NT-
proCNP in critically ill patients. Serum NT-proCNP
concentrations were inversely correlated to parameters
reflecting hepatic biosynthetic capacity, namely albumin
(Figure 3c) and pseudocholinesterase activity (Table 3).
For the total cohort of critically ill patients, as well as
for sepsis patients, we found a strong association of NT-
proCNP serum concentrations at admission to the ICU
and established clinical scores like APACHE II, sequen-
tial organ failure assessment (SOFA) and SAPS2 (Table
3). These findings suggest that NT-proCNP levels are
linked to disease severity in critical illness and in sepsis.
NT-proCNP is a strong predictive marker for ICU and
overall survival in critically ill patients, and a decline of
NT-proCNP levels after admission to the ICU is associated
with a favorable outcome
Based on the clear associations between NT-proCNP,
inflammatory markers, organ dysfunction and prognostic
clinical scores, we hypothesized that NT-proCNP mea-
surements could predict mortality in critically ill medical
patients. We determined NT-proCNP serum concentra-
tions at ICU admission, and at days three and seven of
ICU treatment. Its prognostic impact on ICU and over-
all survival among all critically ill patients and the
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Figure 2 Serum NT-proCNP concentrations in critically ill patients are elevated in sepsis. (a) In patients with sepsis amino-terminal pro-C-
type natriuretic peptide (NT-proCNP) serum concentrations are significantly (P < 0.001, U-test) higher as compared with patients with non-septic
etiology of critical illness. Box plot are displayed, where the bold line indicates the median per group, the box represents 50% of the values, and
horizontal lines show minimum and maximum values of the calculated non-outlier values; asterisks and open circles indicate outlier values. (b)
Receiver operating characteristic (ROC) curve analyses comparing the diagnostic power in predicting sepsis of NT-proCNP in critically ill patients
in a medical ICU (black line, area under the curve (AUC) = 0.661) with classical markers of inflammation and bacterial infection: C-reactive protein
(CRP; grey line, AUC = 0.852), procalcitonin (PCT; dotted black line, AUC = 0.783), and white blood cell count (leucocytes; dotted grey line, AUC
= 0.560).
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Page 5 of 10subgroups of sepsis and non-sepsis patients was assessed
over a long-term follow-up period (median observation
time 348 days, range 29 to 884 days).
Patients that died during the subsequent ICU treat-
ment showed significantly higher NT-proCNP levels at
admission and on day three (Figure 3a and Table 4). On
day seven, a trend to higher NT-proCNP levels in
patients who died in the ICU could be observed, but did
not reach statistical significance. In order to account for
the potential impact of volume load during ICU treat-
ment on NT-proCNP levels, we also normalized NT-
proCNP concentrations to the patients’ current hemato-
crit levels, revealing the same findings as for NT-
proCNP by itself (Table 5).
Moreover, low NT-proCNP levels upon admission to
the ICU and on day three were a strong prognostic predic-
tor for ICU survival (admission P = 0.001, day three P =
0.001, day seven not significant; Cox regression analyses).
In this respect, NT-proCNP levels showed comparable
prognostic accuracy like established multifactorial scores
such as SOFA or the SOFA score change during the first
three days of ICU treatment (AUC = 0.711 for NT-
proCNP, 0.684 for SOFA, and 0.646 for SOFA score
changes in ROC analyses). Kaplan-Meier curves showed,
using a cut-off value for serum NT-proCNP of 8 pmol/L,
significantly improved ICU survival for critically ill patients
with low NT-proCNP levels at admission and on day three
(Figures 3b and 3c, and Table 4). Interestingly, survivors
displayed a significant decrease in NT-proCNP serum
concentrations from admission to day three (P = 0.001;
Figure 3d), while NT-proCNP levels remained stably ele-
vated in non-survivors.
In multivariate Cox regression analyses for variables
obtained at ICU admission including CRP and PCT as
markers of inflammation and infection, NT-proCNP
remained an independent significant prognostic para-
meter. However, if markers of hepatic and renal dys-
function (albumin and creatinine) were included, NT-
proCNP did not reach independent prognostic signifi-
cance (detailed data not shown).
Although the long-term outcome of critically ill
patients is certainly affected by manifold factors, we
also tested whether NT-proCNP levels during the early
course of ICU treatment could predict the long-term
survival. Patients that will die during long-term follow
up had significantly higher NT-proCNP levels than
survivors at ICU admission and day three (Figure 4a).
By Cox regression analyses, high NT-proCNP levels at
admission (P = 0.002) and day three (P =0 . 0 1 3 )p r e -
dicted long-term mortality in critically ill patients. We
also observed a trend to high levels predicting mortal-
ity for NT-proCNP measured at day seven. Using
Kaplan-Meier curves, with cut-off values for serum
NT-proCNP of 8 pmol/L, we demonstrated signifi-
cantly improved overall survival for critically ill
patients with low NT-proCNP (Figures 4b and 4c;
Table 4).
In an analogous manner as for short-term survival, a
decrease in NT-proCNP serum concentrations from day
one to three was associated with a favorable long-term
prognosis. This was displayed by a significant decline in
NT-proCNP levels from admission to day three in survi-
vors (P = 0.010, Figure 4d), but not in non-survivors.
Discussion
NT-proCNP has been recently proposed as a novel diag-
nostic marker for sepsis in traumatized patients without
traumatic brain injury [18]. It was suggested that NT-
proCNP levels above a range of 1.6 to 3.1 pmol/L iden-
tified sepsis with high sensitivity and specificity in these
patients [18]. However, the limited number of investi-
gated patients, as well as the missing evaluation of renal
function and confounding factors such as age, gender,
and body mass index, have been criticized and regarded
as limitations of this prior study [25].
Table 3 Correlations with NT-proCNP serum
concentrations at admission
All patients Sepsis Non-sepsis
Parameters r P r P r P
Markers of
inflammation
Leukocytes 0.178 0.006 0.196 0.011 - n.s.
CRP 0.296 < 0.001 0.205 0.008 - n.s.
Procalcitonin 0.456 < 0.001 0.398 < 0.001 0.316 0.031
IL-6 0.188 0.047 - n.s. - n.s.
TNF-a 0.500 < 0.001 0.444 < 0.001 0.578 0.001
Markers of organ
function
Creatinine 0.715 < 0.001 0.746 < 0.001 0.605 < 0.001
Urea 0.648 < 0.001 0.684 < 0.001 0.459 < 0.001
Cystatin C 0.700 < 0.001 0.757 < 0.001 0.419 0.011
Cystatin C GFR -0.707 < 0.001 -0.749 < 0.001 -0.749 0.002
AP 0.441 0.012 - n.s. - n.s.
PCHE -0.279 < 0.001 -0.214 0.009 -0.310 0.015
Albumin -0.329 < 0.001 -0.311 0.001 - n.s.
Clinical scores
APACHE II 0.206 0.006 0.388 0.001 - n.s.
SOFA 0.261 0.026 - n.s. - n.s.
SAPS2 0.230 0.015 0.361 0.001 - n.s.
r, correlation coefficient; P, P-value; r and P-values by Spearman rank
correlation. AP, alkaline phosphatase; APACHE, Acute Physiology and Chronic
Health Evaluation; CRP, C-reactive protein; GFR, glomerular filtration rate; IL-6,
interleukin 6; NT-proCNP, amino-terminal pro-C-type natriuretic peptide; PCHE,
pseudocholinesterase; SAPS2, simplified acute physiology score; SOFA,
sequential organ failure assessment; TNF-a, tumor necrosis factor a.
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Page 6 of 10In our study, we confirmed that NT-proCNP is acti-
vated in critically ill medical patients. In accordance
with previous data [17,18], sepsis patients showed sig-
nificantly higher NT-proCNP levels than non-sepsis
patients. However, when we compared the diagnostic
accuracy of NT-proCNP levels with routinely used bio-
markers of inflammation and infection, such as CRP,
PCT, and white blood cell count [26,27], NT-proCNP
displayed inferior diagnostic precision for sepsis as com-
pared with classical parameters in medical ICU patients.
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Figure 3 Association of sequentially measured NT-proCNP concentrations with ICU mortality. (a) Patients that die during the course of ICU
treatment have significantly higher serum amino-terminal pro-C-type natriuretic peptide (NT-proCNP) levels on admittance to the ICU (P = 0.001)
and on day 3 (P = 0.001) than survivors. At day 7 no significant changes in NT-proCNP levels between survivors and non-survivors were detected.
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survival curves of ICU patients are displayed, showing that patients with high NT-proCNP levels (> 8 pmol/L, grey) have an increased short-term
mortality in the ICU as compared with patients with low NT-proCNP serum concentrations. P-values are given in the figure. (d) Survivors in the ICU
display a significant decrease in NT-proCNP serum concentrations between day 1 and day 3 (P = 0.001) as compared with non-survivors.
Table 4 NT-proCNP serum concentrations and association
with survival
NT-proCNP median (range) (pmol/L)
Outcome Admission Day 3 Day 7
Survivor ICU 3.28 (0-42) 2.75 (2.3-20) 3.55 (3.6-20)
Death ICU 7.32 (3.4-20) 12.49 (3.2-20) 10.51 (5.6-20)
Survivor overall 2.53 (2.31-20) 2.62 (2.33-20) 3.32 (3.67-20)
Death overall 6.64 (0-20) 7.86 (3.10-20) 8.94 (5.38-20)
NT-proCNP, amino-terminal pro-C-type natriuretic peptide.
Table 5 NT-proCNP serum concentrations (normalized to
hematocrit) and association with survival
NT-proCNP/hematocritmedian (range)
Outcome Admission Day 3 Day 7
Survivor ICU 9.92 (0-191) 9.30 (0-175) 11.30 (0-191)
Death ICU 21.35 (0-221) 39.02 (0-200) 36.24 (0-168)
Survivor overall 7.67 (0-191) 9.04 (0-175) 9.51 (0-175)
Death overall 20.0 (0-221) 22.60 (0-200) 29.79 (0-168)
NT-proCNP, amino-terminal pro-C-type natriuretic peptide.
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Page 7 of 10In animal models, the regulation of CNP depends on a
variety of influencing factors such as glucocorticoids,
thyroid hormones, vasoactive peptides, and catabolic
state [28-32], but very little is known about regulatory
mechanisms in states of critical illness in humans. Using
correlation analyses, our study revealed significant asso-
ciations between NT-proCNP and established laboratory
biomarkers reflecting inflammation and organ function
in medical ICU patients.
CNP itself is widely expressed in the vasculature,
and highest concentrations are found in the endothe-
lium [15]. Inflammatory cytokines such as IL-1, TNF-
a, and endotoxin are known to trigger the release of
CNP from endothelial cells in animal models [14],
which fits well to the close correlation of serum NT-
proCNP with serum TNF-a,P C T ,C R P ,a n dl e u k o -
cytes in our cohort of critically ill patients. Of note,
this association could not be observed for IL-6,
although IL-6 serum levels were strongly increased in
sepsis patients. However, we did not measure addi-
tional parameters of the NO and prostaglandin system
such as nitrate, nitrite, prostacyclin, or thromboxane
levels, because most of these parameters are rather
u n s t a b l e ,e v e na t4 ° C ,m a k i n ga na p p r o p r i a t ep r e - a n a -
lytic sample acquisition in the ICU setting with a large
p a t i e n tc o h o r td i f f i c u l t .W et h e r e f o r ec a n n o te s t i m a t e
the impact of these systems on the NT-proCNP levels
in critical illness.
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Figure 4 Association of sequentially measured NT-proCNP concentrations with long-term mortality. (a) Serum amino-terminal pro-C-type
natriuretic peptide (NT-proCNP) concentrations are significantly associated with the overall survival of critically ill patients. Survivors have
significantly lower serum NT-proCNP levels on admittance to the ICU (P = 0.002) and on day 3 (P = 0.013). Box plot are displayed, where the
bold line indicates the median per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of
the calculated non-outlier values; asterisks and open circles indicate outlier values. (b and c) Kaplan-Meier survival curves of ICU patients are
displayed, showing increased overall mortality in the long-term follow up of patients with high NT-proCNP levels (on admission > 8 pmol/L,
grey) as compared with patients with low NT-proCNP serum concentrations. P-values are given in the figure. (d) Likewise in patients surviving
ICU treatment, long-term survivors showed a significant decline of NT-proCNP serum between day 1 and day 3 (P = 0.010).
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Page 8 of 10The pathophysiological consequences of high circulat-
ing NT-proCNP in critically ill patients are not clear at
present. Very recently, CNP has also been described as a
regulator of glucose metabolism by acting as an inhibi-
tor of insulin action [33]. In a novel mouse model of
inducible CNP-depletion, CNP-deficient mice were
found to have reduced food intake, lower endogenous
insulin levels, and a significantly reduced insulin toler-
ance [33]. Interestingly, NT-proCNP in critically ill
patients was indeed correlated with endogenous insulin
levels (C-peptide) as well as serum resistin and retinol-
binding protein 4, two mediators of insulin resistance
(data not shown) [23,34]. Further studies are needed to
elucidate the potential pathogenic function of NT-
proCNP, especially its possible involvement in promot-
ing insulin resistance and metabolic dysregulation in the
critically ill.
Our study is the first to demonstrate the prognostic
value of NT-proCNP measurements in medical ICU
patients. NT-proCNP serum concentrations upon
admission as well as on day three were closely asso-
ciated with ICU survival as well as long-term survival,
and high NT-proCNP levels indicated an unfavorable
prognosis. Surviving patients displayed an individual
decline of NT-proCNP between days one and three.
However, we would like to emphasize that the prognos-
tic power of NT-proCNP as a biomarker is dependent
o nr e n a lf u n c t i o na sw e l la sh e p a t i cf u n c t i o n ,t h e r e b y
limiting the general use of any static cut-off (e.g., 8
pmol/L as shown in Kaplan-Meier curves). Larger stu-
dies should evaluate whether adjustment of NT-proCNP
to individual renal and hepatic functions might further
improve its diagnostic power.
Conclusions
NT-proCNP was significantly elevated in critically ill
patients with highest levels in sepsis. Inflammation as
well as organ function strongly impact NT-proCNP con-
centrations. Low NT-proCNP levels and a decline dur-
ing initial treatment were associated with favorable ICU
and long-term outcomes. The predictive power of
serum NT-proCNP was similar to ‘conventional’ prog-
nostic tools such as clinical scores. Yet, further studies
are needed to elucidate the underlying pathomechan-
isms of NT-proCNP in patients with critical illness.
Key messages
￿ NT-proCNP, a paracrine molecule released mainly
from vasculature, has been implicated in inflamma-
tory and metabolic pathways and has been recently
proposed as a novel biomarker for predicting sepsis
in traumatized patients.
￿ In critically ill medical patients, NT-proCNP serum
concentrations upon ICU admission are elevated as
compared with healthy controls and are higher in
sepsis patients than in non-sepsis patients.
￿ In the initial course of ICU treatment, NT-proCNP
serum concentrations significantly decline between
admission and day three.
￿ NT-proCNP levels at admission to the ICU are
correlated to biomarkers of inflammation, organ dys-
function, and disease severity.
￿ NT-proCNP is a strong outcome predictor, and a
decline of NT-proCNP serum concentrations after
ICU admission is associated with a reduced mortality.
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